Literature DB >> 8081556

Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

F M Marincola1, P Shamamian, T B Simonis, A Abati, J Hackett, T O'Dea, P Fetsch, J Yannelli, N P Restifo, J J Mulé.   

Abstract

Surface expression of human leukocyte antigen (HLA) class I antigens on melanoma lines was evaluated by locus-specific monoclonal antibodies (mAbs) with three different techniques: Fluorescence-activated cell sorting (FACS), immunohistochemistry with cytospin preparation (ICP), and complement-mediated cytotoxicity (CMC). Eleven HLA class I-expressing cell lines developed from metastases were used. Specific expression of HLA loci was examined under routine culture conditions and after 48-h incubation in interferon-gamma (IFN-gamma; 500 U/ml). Loss of allelic expression was seen in one line (586-MEL): Products of genes coding for HLA-A29 and -B44, in strong linkage disequilibrium, were not detectable. HLA-A antigens were consistently detected by all methodologies and minimally affected by pretreatment with IFN-gamma. HLA-B antigens were detectable in 8 of 11 lines by ICP and 3 of 11 lines by CMC. By FACS the supratypic specificity HLA-Bw6 was expressed at low levels in most lines (mean fluorescence 47.2 +/- 13.4 and rose to 259.8 +/- 45.9 after incubation with IFN-gamma; p < 0.001). HLA-Cw antigen detection by CMC correlated with HLA-B (p < 0.01), suggesting that down-regulation and sensitivity to IFN-gamma are shared by the two loci. This low expression of the HLA-B antigens may play a role in the evasion of the host immune response and its up-regulation may be useful in allowing tumor antigen recognition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081556      PMCID: PMC2561308          DOI: 10.1097/00002371-199407000-00002

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  41 in total

1.  A monoclonal antibody against HLA-A11 and A24.

Authors:  S K Foung; B Taidi; D Ness; F C Grumet
Journal:  Hum Immunol       Date:  1986-03       Impact factor: 2.850

2.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

3.  Monoclonal antibody to HLA-A3.

Authors:  A E Berger; J E Davis; P Cresswell
Journal:  Hybridoma       Date:  1982

4.  A monoclonal antibody directed against the HLA-Bw6 epitope.

Authors:  S F Radka; D D Kostyu; D B Amos
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

5.  Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma.

Authors:  G D'Alessandro; I Zardawi; J Grace; W H McCarthy; P Hersey
Journal:  Pathology       Date:  1987-10       Impact factor: 5.306

6.  Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.

Authors:  B Holzmann; E B Bröcker; J M Lehmann; D J Ruiter; C Sorg; G Riethmüller; J P Johnson
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

9.  Phenotypic dynamics of tumor progression in human malignant melanoma.

Authors:  E B Bröcker; L Suter; J Brüggen; D J Ruiter; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

10.  Specificity of monoclonal antibodies directed against human and murine class II histocompatibility antigens as analyzed by binding to HLA-deletion mutant cell lines.

Authors:  S Shaw; A Ziegler; R DeMars
Journal:  Hum Immunol       Date:  1985-04       Impact factor: 2.850

View more
  15 in total

1.  CD29 identifies IFN-γ-producing human CD8+ T cells with an increased cytotoxic potential.

Authors:  Benoît P Nicolet; Aurélie Guislain; Floris P J van Alphen; Raquel Gomez-Eerland; Ton N M Schumacher; Maartje van den Biggelaar; Monika C Wolkers
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

Review 2.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.

Authors:  Samuel T Haile; Jacobus J Bosch; Nnenna I Agu; Annette M Zeender; Preethi Somasundaram; Minu K Srivastava; Sabine Britting; Julie B Wolf; Bruce R Ksander; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2011-05-09       Impact factor: 5.422

4.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

5.  HLA associations in the antitumor response against malignant melanoma.

Authors:  F M Marincola; P Shamamian; L Rivoltini; M Salgaller; J Cormier; N P Restifo; T B Simonis; D Venzon; D E White; D R Parkinson
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-11

6.  A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Authors:  Evripidis Lanitis; Jenessa B Smith; Denarda Dangaj; Seleeke Flingai; Mathilde Poussin; Shuwen Xu; Brian J Czerniecki; Yong F Li; Paul F Robbins; Daniel J Powell
Journal:  Hum Gene Ther       Date:  2014-08       Impact factor: 5.695

7.  Adenosine receptors regulate exosome production.

Authors:  Nils Ludwig; Juliana H Azambuja; Aparna Rao; Delbert G Gillespie; Edwin K Jackson; Theresa L Whiteside
Journal:  Purinergic Signal       Date:  2020-05-22       Impact factor: 3.765

8.  Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Authors:  R F Wang; P F Robbins; Y Kawakami; X Q Kang; S A Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

9.  Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes.

Authors:  D C Spierings; E Agsteribbe; J Wilschut; A Huckriede
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

10.  Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Authors:  Paul F Robbins; Yong-Chen Lu; Mona El-Gamil; Yong F Li; Colin Gross; Jared Gartner; Jimmy C Lin; Jamie K Teer; Paul Cliften; Eric Tycksen; Yardena Samuels; Steven A Rosenberg
Journal:  Nat Med       Date:  2013-05-05       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.